Skip to main content
S&P 5007,551.81-0.45%DOW51,461.90-1.21%NASDAQ25,978.42-0.01%BTC$76,346.00+0.85%ETH$2,420.07+0.87%GOLD$4,327.00-1.38%OIL$101.32-1.08%
Smart Investors Daily
CA

NASDAQ · CAMP

CAMP4 Therapeutics Corporation

Healthcare · Biotechnology

$3.86

Down-$0.33 (-7.88%)

Updated Sep 17, 2026, 2:36 AM

SID Score

4.4/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
125.74M
P/E ratio
-2.24
Dividend yield
0.00%
52-week range
$2.90 – $7.75
Volume
300.79K
Avg. volume
166.84K

Price performance

CAMP price history

1M range · 20 trading sessions · Daily adjusted prices

CAMP closed at $3.86 after 20 trading sessions, down 16.99% for the selected period.

Last close
$3.86
Period change
-16.99%
Period low
$3.79
Period high
$4.65
Daily close
View OHLC price history
CAMP OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Sep 16, 2026$4.19$4.37$3.84$3.86300.79K
Sep 15, 2026$4.23$4.275$4.03$4.19175.27K
Sep 14, 2026$4.26$4.49$4.18$4.25167.04K
Sep 11, 2026$4.46$4.54$4.21$4.25101.15K
Sep 10, 2026$4.30$4.495$4.145$4.34115.64K
Sep 9, 2026$4.45$4.50$4.33$4.3379.92K
Sep 8, 2026$4.40$4.53$4.30$4.40280.48K
Sep 4, 2026$4.45$4.64$4.331$4.41131.12K
Sep 3, 2026$3.87$4.53$3.76$4.491.28M
Sep 2, 2026$3.85$4.0695$3.78$3.80215.2K
Sep 1, 2026$3.85$3.95$3.70$3.79229.39K
Aug 31, 2026$4.18$4.18$3.87$3.96190.29K
Aug 28, 2026$4.18$4.30$4.03$4.15142.06K
Aug 27, 2026$4.23$4.41$4.01$4.14749.4K
Aug 26, 2026$4.45$4.5283$4.05$4.20364.5K
Aug 25, 2026$4.40$4.60$4.33$4.45184.48K
Aug 24, 2026$4.46$4.5173$4.26$4.32109.48K
Aug 21, 2026$4.50$4.5408$4.42$4.48126.86K
Aug 20, 2026$4.57$4.9499$4.37$4.46395.65K
Aug 19, 2026$4.97$5.035$4.58$4.65228.5K

Latest CAMP news

The latest Smart Investors Daily articles mentioning CAMP.

Stock researchCompany · Overview

CAMP research

Overview

Company profile and research snapshot.

Company profile

Camp4 Therapeutics Corp is a clinical stage biopharmaceutical company pioneering the discovery and development of regulatory RNA-based therapeutics to upregulate gene expression and restore healthy protein levels to treat various genetic diseases. It focuses on genetic diseases of the central nervous system and liver. The group's pipeline products are CMP-CPS-001 and CMP-SYNGAP.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Buy
Average target
$7.00
Implied upside
—
Analysts
12
CAMP recent ratings
DateFirmRatingTarget
Aug 14, 2026Piper SandlerOverweight—
Jun 16, 2026JP MorganOverweight—
Jun 10, 2026Chardan CapitalBuy—
Apr 14, 2026Rodman & RenshawBuy—
Apr 2, 2026Leerink PartnersOutperform—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 8, 2026

CAMP4 Therapeutics to Host Virtual Analyst Day to Discuss CMP-002 for the Treatment of SYNGAP1-Related Disorder on September 28, 2026

WATERTOWN, Mass., Sept. 08, 2026 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation (“CAMP4”) (Nasdaq: CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting therapeutics designed to upregulate gene expression with the goal of restoring healthy protein levels to treat a broad range of genetic diseases, will host a virtual Analyst Day on Monday, September 28, 2026 from 12:00 – 1:30 PM ET featuring presentations and Q&A led by CAMP4’s executive leadersh

Yahoo · Sep 1, 2026

CAMP4 to Participate in Upcoming Investor Conferences

WATERTOWN, Mass., Sept. 01, 2026 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation (“CAMP4” or “the Company”) (Nasdaq: CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting therapeutics designed to upregulate gene expression with the goal of restoring healthy protein levels to treat a broad range of genetic diseases, today announced that the Company will participate in the following upcoming investor conferences: Wells Fargo 21st Annual Healthcare C

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By